Inclusion Criteria:  Patient ≥ 18 years Patients with histological confirmation of mCRC Patient who started treatment with regorafenib for mCRC according to usual clinical practice during or after January 2017 and at least 3 months prior to the inclusion in the study  Exclusion Criteria:  Patient who have been treated with regorafenib during their participation in a clinical trial